# A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

> **NCT07417306** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.** · enrollment: 912 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** HDM1005 1
- **DRUG:** HDM1005 2
- **DRUG:** Mazdutide

## Key facts

- **NCT ID:** NCT07417306
- **Lead sponsor:** Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-27
- **Primary completion:** 2027-08-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 912 (ESTIMATED)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07417306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07417306, "A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07417306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*